The Landscape Of Naloxone Access With HRT’s Michael Hufford
In this episode, HBW Insight speaks to Michael Hufford, co-founder and CEO of Harm Reduction Therapeutics about the inaccessibility of naloxone, a life-saving opioid overdose antidote. Hufford unpacks on the history of naloxone access and explains why standing orders aren’t as helpful as they seem. We also explore the incentives for companies currently producing prescription naloxone to make the switch to OTC status—and why many of them have chosen not to. While the financial incentive may not be there, the public health need is dire, and Hufford explains the importance of Harm Reduction Groups and non-profit pharmaceutical companies for getting naloxone into the hands of those who need it the most.